SAR-442257

SAR-442257 (0.001-10 nM; 48 h) potently reduces primary multiple myeloma cell viability ex vivo with picomolar EC₅₀ valuesl^[1].
SAR-442257 (1 nM; 48 h) induces significant degranulation of endogenous CD3+ T cells in bone marrow mononuclear cells (MNCs) derived from multiple myeloma samples^[1].
SAR-442257 (1 nM; 48 h)-mediated cytotoxicity against primary multiple myeloma cells is dependent on the presence of endogenous CD3+ T cells^[1].
SAR-442257 (1 nM; 48 h) response in primary multiple myeloma samples has surface CD38 expression (6-fold higher MFI on multiple myeloma cells vs. non-myeloma cells) as the strongest biomarker, while a very low E:T ratio may contribute to resistance^[1].
SAR-442257 (1 nM, 10 nM, 100 nM, 1000 nM; 7.5 min) enhances T cell-to-multiple myeloma cell binding avidity, inducing a 1.5-fold higher frequency of bound T cells in U266 and MM1S cell lines compared to the CD38-CD3 bispecific antibody^[2].
SAR-442257 (0.01-16 nM; 24 h) potently induces dose-dependent cytotoxicity against 10 human multiple myeloma cell lines, with EC₅₀ values of 0.02 nM (MM1S) and 0.2 nM (U266), and reduces cell viability by 58-97% at 1 nM after 24 h^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.